Skip to main content
Veterinary Medicines

Enrox Flavour 150 mg Tablets for dogs

Authorised
  • Enrofloxacin

Product identification

Medicine name:
Enrox Flavour 150 mg Tablets for dogs
Enroxil flavour 150 mg tabletes suņiem
Active substance:
  • Enrofloxacin
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Enrofloxacin
    150.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ01MA90
Authorisation status:
  • Valid
Authorised in:
  • Latvia
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • KRKA tovarna zdravil d.d. Novo mesto
Marketing authorisation date:
Manufacturing sites for batch release:
  • KRKA tovarna zdravil d.d. Novo mesto
  • Virbac
  • Krka-Farma d.o.o.
Responsible authority:
  • Food And Veterinary Service
Authorisation number:
  • V/DCP/08/1619
Date of authorisation status change:
Reference member state:
  • Ireland
Procedure number:
  • IE/V/0423/003
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Czechia
  • Denmark
  • Germany
  • Greece
  • Hungary
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Netherlands
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

English (PDF)
Published on: 15/12/2024
Download

Combined File of all Documents

English (PDF)
Published on: 15/12/2024
Download
Latvian (PDF)
Published on: 10/01/2025
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."